Medicine
Mounjaro KwikPen 40.08 mg/2.4 mL injection
Mounjaro KwikPen 40.08 mg/2.4 mL injection is a prescription medicine containing Tirzepatide for subcutaneous use, marketed by Eli Lilly, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store MOUNJARO single-dose pen and single-dose vial in a refrigerator at 2°C…
Key facts
- Active ingredient (INN)
- Tirzepatide
- Brand
- Mounjaro KwikPen
- Strength
- 40.08 mg/2.4 mL
- Dosage form
- Injection
- Route
- Subcutaneous
- Packs
- 1 syringe of 2.4 mL
- Marketing authorisation holder
- Eli Lilly
- Manufacturer
- Eli Lilly
- Origin register
- US FDA, United States
- Storage
- Store MOUNJARO single-dose pen and single-dose vial in a refrigerator at 2°C to 8°C (36°F to 46°F). Discard the single-dose pen or single-dose vial after a total of 21 days at room temperature. If needed, each single-dose pen or single-dose vial can be stored unrefrigerated at temperatures not to exceed 30°C (86°F) for up to a total of 21 days.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- A10BX16 Tirzepatide
- HS code (indicative)
- 3004.39Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 20 January 2026
- Identifiers
- RxCUI 2601743, 2601746, 2601755 +7DailyMed set ID d2d7da5d-ad07-4228-955f-cf7e355c8cc0NDC 0002-3433Application NDA215866
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 syringe in 1 carton / 2.4 mL in 1 syringe | 0002-3433-11 | Eli Lilly | 20 January 2026 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Tirzepatide 40.08 mg/2.4 mL injection.
Other strengths and forms of Tirzepatide
Clinical summary
Tirzepatide is a GLP-1 receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. MedsAcross supplies Tirzepatide for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about TirzepatideFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Mounjaro prescribing information (Eli Lilly) · U.S. National Library of Medicine, DailyMed
- Mounjaro: European public assessment report (EPAR) · European Medicines Agency
Need Mounjaro KwikPen 40.08 mg/2.4 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.